Vitamin D: excess and interactions
How to account for total vitamin D intake, recognise signs of excess and check combinations with medicines.
Key points
- For adults, the US upper limit is 4,000 IU vitamin D daily from food and supplements combined. This is a limit, not an intake target. [1] See the evidence 1 2
- Excess vitamin D can raise blood calcium and cause nausea, weakness or thirst. Check the amount of vitamin D in all products you take. [1] See the evidence 1 2
Practical guide
Please double-check the conclusions and consider your own circumstances when choosing a supplement.
When taking vitamin D, consider all sources and medicines. Safety also depends on health conditions and total calcium intake.
Amount and signs of excess
Why these conclusions
Excess vitamin D and calcium
Elevated calcium from excess vitamin D may be accompanied by vomiting, frequent urination and kidney stones. Severe toxicity can damage the kidneys and cause arrhythmia. If you have nausea, vomiting, weakness, extreme thirst or frequent urination, seek medical assessment and show the ingredients and doses of all products. These symptoms alone do not establish the cause. [1]
In a three-year study of healthy adults aged 55–70 assigned 400, 4,000 or 10,000 IU D3 daily, at least one episode of elevated blood calcium was found in 0 of 124, 4 of 125 and 11 of 124 people, respectively. All episodes were mild and resolved on repeat testing; some participants reduced calcium intake before that test. [2]
Elevated urinary calcium was found at least once in 21 of 124, 28 of 125 and 38 of 124 participants in these three groups, respectively. These were laboratory episodes, not the frequency of kidney failure. [2] [1]
In the study, participants with low dietary calcium received an additional 300 or 600 mg elemental calcium daily. In the group assigned 10,000 IU, D3 content declined in two batches and, after months 18–24, the actual daily dose until study end was estimated at 2,000–10,000 IU. [2] [3]
In a seven-year study of postmenopausal women, 1,000 mg calcium and 400 IU vitamin D daily increased the relative risk of kidney stones by 17% versus placebo in the setting of high total calcium intake. [1]
Vitamin D aids calcium absorption; calcium needs are assessed separately based on the whole diet. The supplied sources do not establish that every buyer must take D with magnesium or K2.
| Parameter | Data |
|---|---|
| Result | Vitamin D aids calcium absorption; calcium needs are assessed separately based on the whole diet. The supplied sources do not establish that every buyer must take D with magnesium or K2. |
| Participants | People considering D, magnesium, K2 and calcium supplements |
| Form | vitamin D and calcium; magnesium and K2 as possible products |
| Dose | No universal combination dose established |
| Dose basis | total dietary calcium intake |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
Check the composition of all products you take to account for total vitamin D; the specific schedule for combining supplements depends on ingredients and medicines.
| Parameter | Data |
|---|---|
| Result | Check the composition of all products you take to account for total vitamin D; the specific schedule for combining supplements depends on ingredients and medicines. |
| Participants | People taking several supplements |
| Form | products containing D3 or other vitamin D |
| Dose | sum of amounts in the servings used |
| Dose basis | all products taken and their labelled servings |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
In a seven-year study of postmenopausal women, 1,000 mg calcium plus 400 IU vitamin D daily increased kidney stone risk by 17% relative to placebo in the setting of high total calcium intake.
| Parameter | Data |
|---|---|
| Result | relative risk increase 17%; absolute risk was not reported in the captured excerpt |
| Participants | 36,282 postmenopausal women in a randomised study |
| Form | Calcium and vitamin D supplements; the specific chemical form was not specified in the captured NIH excerpt |
| Dose | 1,000 mg calcium + 10 µg (400 IU) vitamin D daily |
| Dose basis | assigned supplements daily; total intake includes food and supplements |
| Comparison | placebo |
| Duration | 7 years |
| Confidence | 2/4: One large randomised study in a postmenopausal population with high total calcium intake; the source does not establish the effect of vitamin D separately from calcium; absolute risk and the interval around the estimate are absent from the captured excerpt. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
Excess vitamin D can raise blood calcium: nausea, vomiting, weakness, thirst, frequent urination and kidney stones may occur; severe toxicity can damage the kidneys and cause arrhythmia.
| Parameter | Data |
|---|---|
| Result | Excess vitamin D can raise blood calcium: nausea, vomiting, weakness, thirst, frequent urination and kidney stones may occur; severe toxicity can damage the kidneys and cause arrhythmia. |
| Participants | People with toxic vitamin D excess |
| Form | vitamin D, mainly from supplements |
| Dose | No fixed toxic dose; signs depend on the excess |
| Dose basis | elevated blood and urinary calcium |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
For adults, the FNB specifies an upper limit of 100 µg (4,000 IU) daily from food and supplements—this is a limit, not a target dose.
| Parameter | Data |
|---|---|
| Result | For adults, the FNB specifies an upper limit of 100 µg (4,000 IU) daily from food and supplements—this is a limit, not a target dose. |
| Participants | Adults aged 19 and over |
| Form | vitamin D from food and supplements |
| Dose | UL 100 µg (4,000 IU)/day |
| Dose basis | total daily intake |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
If you have high calcium, kidney disease or hyperparathyroidism, discuss vitamin D and all medicines with a doctor. Vitamin D increases calcium absorption and with thiazide diuretics may cause hypercalcaemia, especially with impaired kidney function and hyperparathyroidism.
| Parameter | Data |
|---|---|
| Result | If you have high calcium, kidney disease or hyperparathyroidism, discuss vitamin D and all medicines with a doctor. Vitamin D increases calcium absorption and with thiazide diuretics may cause hypercalcaemia, especially with impaired kidney function and hyperparathyroidism. |
| Participants | People with high calcium, impaired kidney function or hyperparathyroidism; increased risk on thiazides |
| Form | vitamin D and a thiazide diuretic |
| Dose | No specific dose stated in the source |
| Dose basis | combination of supplement and medicine |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
Orlistat with a reduced-fat diet can reduce vitamin D absorption. Corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism; thiazides with vitamin D can raise blood calcium. High vitamin D doses may also reduce the effect of some statins; discuss all medicines and supplements with a doctor.
| Parameter | Data |
|---|---|
| Result | Orlistat with a reduced-fat diet can reduce vitamin D absorption. Corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism; thiazides with vitamin D can raise blood calcium. High vitamin D doses may also reduce the effect of some statins; discuss all medicines and supplements with a doctor. |
| Participants | People taking orlistat, corticosteroids, thiazides or some statins |
| Form | oral vitamin D and the relevant medicine |
| Dose | Doses not stated; high vitamin D intake is mentioned for statins |
| Dose basis | specific combination; medicines do not all behave identically |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
Nausea, vomiting, weakness, extreme thirst and frequent urination may accompany elevated calcium caused by excess vitamin D. Seek medical assessment for these symptoms and show the ingredients and doses of all products taken: symptoms alone do not establish the cause.
| Parameter | Data |
|---|---|
| Result | Nausea, vomiting, weakness, extreme thirst and frequent urination may accompany elevated calcium caused by excess vitamin D. Seek medical assessment for these symptoms and show the ingredients and doses of all products taken: symptoms alone do not establish the cause. |
| Participants | People with the listed symptoms taking several supplements |
| Form | vitamin D and other supplements |
| Dose | Dose not established; ingredients and doses need checking |
| Dose basis | symptoms and potential excess; causation not established |
| Comparison | Not applicable: a descriptive fact or an organisation’s recommendation, not a comparison of study groups. |
| Duration | Not applicable: the source describes a fact or standard, not an observation over a fixed period. |
| Confidence | A descriptive fact, summary of an official recommendation or rule; the effectiveness rating scale does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
In a three-year study in adults aged 55–70, at least one laboratory episode of hypercalcaemia was found in 0 of 124, 4 of 125 and 11 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively. All episodes were mild and resolved on repeat testing; some participants reduced calcium intake before that test.
| Parameter | Data |
|---|---|
| Result | In a three-year study in adults aged 55–70, at least one laboratory episode of hypercalcaemia was found in 0 of 124, 4 of 125 and 11 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively. All episodes were mild and resolved on repeat testing; some participants reduced calcium intake before that test. |
| Participants | 373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose. |
| Form | Liquid oral cholecalciferol D3, Ddrops |
| Dose | Assigned 400, 4,000 or 10,000 IU daily |
| Dose basis | IU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted. |
| Comparison | Other randomised active-dose groups; reference 400 IU/day, no placebo |
| Duration | 3 years |
| Confidence | low: The blinded randomised study directly measured laboratory markers. Confidence was downgraded one level because the actual dose in the 10,000 IU group was uncertain after content fell in two batches between months 18 and 24; through month 36 the dose was estimated at 2,000–10,000 IU/day. Another downgrade reflects imprecision of the comparative estimate: 15 people had hypercalcaemia and no verified pairwise interval is available. A single study or diagnosis alone was not a reason for downgrading. |
| Volume of evidence | 1 |
| Sources | [2] |
In the same study, laboratory hypercalciuria was found at least once in 21 of 124, 28 of 125 and 38 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively; approximately 17%, 22% and 31%. This is a urinary calcium measure, not kidney failure frequency.
| Parameter | Data |
|---|---|
| Result | In the same study, laboratory hypercalciuria was found at least once in 21 of 124, 28 of 125 and 38 of 124 participants assigned 400, 4,000 and 10,000 IU D3 daily, respectively; approximately 17%, 22% and 31%. This is a urinary calcium measure, not kidney failure frequency. |
| Participants | 373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose. |
| Form | Liquid oral cholecalciferol D3, Ddrops |
| Dose | Assigned 400, 4,000 or 10,000 IU daily |
| Dose basis | IU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted. |
| Comparison | Other randomised active-dose groups; reference 400 IU/day, no placebo |
| Duration | 3 years |
| Confidence | moderate: The blinded randomised study prespecified and repeatedly measured the urinary outcome; 87 participants had an episode, dose trend p=0.01. Confidence was downgraded one level because product content fell in the high-dose group. There was no additional downgrade for imprecision of the presence of a trend or inconsistency in a single study; pairwise precision is not established. |
| Volume of evidence | 1 |
| Sources | [2] |
The US FNB sets an upper limit for adults of 4,000 IU (100 µg) vitamin D daily from food, drinks and supplements. This is not a target dose, toxicity threshold or guarantee of individual safety.
| Parameter | Data |
|---|---|
| Result | The US FNB sets an upper limit for adults of 4,000 IU (100 µg) vitamin D daily from food, drinks and supplements. This is not a target dose, toxicity threshold or guarantee of individual safety. |
| Participants | Adults in the US |
| Form | Vitamin D from food, drinks and supplements |
| Dose | 4,000 IU (100 µg) daily |
| Dose basis | Total intake from all food sources and supplements |
| Comparison | Official standard, not a comparative study |
| Duration | Daily reference |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
Excess vitamin D, usually associated with excessive supplement intake, can raise blood and urinary calcium. Hypercalcaemia may be accompanied by nausea, weakness, thirst, frequent urination and stones; extremely severe toxicity can cause kidney failure.
| Parameter | Data |
|---|---|
| Result | Excess vitamin D, usually associated with excessive supplement intake, can raise blood and urinary calcium. Hypercalcaemia may be accompanied by nausea, weakness, thirst, frequent urination and stones; extremely severe toxicity can cause kidney failure. |
| Participants | People with excessive vitamin D intake |
| Form | Vitamin D supplements |
| Dose | No single toxic dose established |
| Dose basis | Total intake and individual circumstances |
| Comparison | Safety description, not a comparative study |
| Duration | Time to onset not established |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
In the study, participants with low dietary calcium received an additional 300 or 600 mg elemental calcium daily, aiming for approximately 1,200 mg total intake; 263 people started the supplement at randomisation. Of 15 participants with hypercalcaemia, 10 were taking calcium at that time; results relate to this protocol.
| Parameter | Data |
|---|---|
| Result | In the study, participants with low dietary calcium received an additional 300 or 600 mg elemental calcium daily, aiming for approximately 1,200 mg total intake; 263 people started the supplement at randomisation. Of 15 participants with hypercalcaemia, 10 were taking calcium at that time; results relate to this protocol. |
| Participants | 373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose. |
| Form | Oral elemental calcium with D3 |
| Dose | 300 or 600 mg elemental calcium daily as needed |
| Dose basis | Mass of elemental calcium; target total intake includes food |
| Comparison | Calcium assigned according to dietary need in each D3 group |
| Duration | Up to 3 years; calcium intake could change |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [2] |
Participants were assigned 400, 4,000 or 10,000 IU D3 daily; no more than an additional 200 IU daily was allowed. In the 10,000 IU group, content in two batches declined between months 18 and 24, and through month 36 the actual dose was estimated at 2,000–10,000 IU daily.
| Parameter | Data |
|---|---|
| Result | Participants were assigned 400, 4,000 or 10,000 IU D3 daily; no more than an additional 200 IU daily was allowed. In the 10,000 IU group, content in two batches declined between months 18 and 24, and through month 36 the actual dose was estimated at 2,000–10,000 IU daily. |
| Participants | 373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose. |
| Form | Liquid oral cholecalciferol D3, Ddrops |
| Dose | Assigned 400, 4,000 or 10,000 IU daily |
| Dose basis | IU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted. |
| Comparison | Other randomised active-dose groups; reference 400 IU/day, no placebo |
| Duration | 3 years |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 2 |
| Sources | [2] [3] |
Thiazide diuretics reduce urinary calcium excretion; combining them with vitamin D may cause hypercalcaemia, especially in older people and those with impaired kidney function or hyperparathyroidism. A numerical frequency for this interaction is not established here.
| Parameter | Data |
|---|---|
| Result | Thiazide diuretics reduce urinary calcium excretion; combining them with vitamin D may cause hypercalcaemia, especially in older people and those with impaired kidney function or hyperparathyroidism. A numerical frequency for this interaction is not established here. |
| Participants | People taking thiazide diuretics, especially older people and those with impaired kidney function or hyperparathyroidism |
| Form | Vitamin D supplements and thiazide diuretics |
| Dose | No dose threshold stated for the interaction |
| Dose basis | Qualitative description of interaction |
| Comparison | Not applicable to a description of interaction |
| Duration | With concurrent use; exact time not stated |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
Orlistat combined with a reduced-fat diet can reduce absorption of vitamin D from food and supplements and lower 25(OH)D. This is a separate interaction, not a subgroup result from the Calgary study.
| Parameter | Data |
|---|---|
| Result | Orlistat combined with a reduced-fat diet can reduce absorption of vitamin D from food and supplements and lower 25(OH)D. This is a separate interaction, not a subgroup result from the Calgary study. |
| Participants | People taking orlistat on a reduced-fat diet |
| Form | Vitamin D from food and supplements |
| Dose | No dose threshold stated for the interaction |
| Dose basis | Qualitative description of interaction |
| Comparison | Not applicable to a description of interaction |
| Duration | With concurrent use; exact time not stated |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 1 |
| Sources | [1] |
The Calgary study percentages refer to laboratory episodes of hypercalcaemia and hypercalciuria in selected participants, not the frequency of kidney failure. These results do not establish equal safety in chronic kidney disease, in all people with stones, or with uncontrolled supplement use.
| Parameter | Data |
|---|---|
| Result | The Calgary study percentages refer to laboratory episodes of hypercalcaemia and hypercalciuria in selected participants, not the frequency of kidney failure. These results do not establish equal safety in chronic kidney disease, in all people with stones, or with uncontrolled supplement use. |
| Participants | 373 healthy men and postmenopausal women aged 55–70 in the Calgary area. Baseline 25(OH)D 30–125 nmol/L, bone density T-score above −2.5. Participants with abnormal baseline blood calcium, recent supplement use over 2,000 IU/day, bone-active medication or vitamin D metabolism disorders were excluded. All 373 received at least one dose. |
| Form | Liquid oral cholecalciferol D3, Ddrops |
| Dose | Assigned 400, 4,000 or 10,000 IU daily |
| Dose basis | IU of D3 activity in the study supplement per day. Five drops daily contained the assigned 80, 800 or 2,000 IU per drop. Dietary vitamin D was counted separately; up to 200 IU/day outside the study was permitted. |
| Comparison | Other randomised active-dose groups; reference 400 IU/day, no placebo |
| Duration | 3 years |
| Confidence | not applicable: An official standard, source-described safety or interaction fact, or study-method context. An effectiveness rating does not apply. |
| Volume of evidence | Named sources: 2 |
| Sources | [2] [1] |
Drug interactions
| Medicine | Interaction | What to consider | Sources |
|---|---|---|---|
| Thiazide diuretics, for example hydrochlorothiazide | Combining with vitamin D can raise blood calcium; risk is higher in older people and those with impaired kidney function or hyperparathyroidism. | Before starting a supplement, discuss its dose with a doctor; if you have impaired kidney function or hyperparathyroidism, or are older, ask whether blood calcium monitoring is needed. | [1] [4] |
| Orlistat, for example Xenical | Orlistat with a reduced-fat diet can reduce absorption of vitamin D from food and supplements. 25(OH)D levels may fall. | The FDA label for Xenical says to take a multivitamin containing fat-soluble vitamins at least 2 hours before or 2 hours after Xenical, or at bedtime; check your own medicine’s instructions. | [1] [5] |
| Systemic corticosteroids, for example prednisone | Systemic corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism; long-term use is also associated with bone loss. | With long-term use, discuss calcium and vitamin D intake, bone loss risk and the need for bone density testing with a doctor. | [1] [6] |
| Some statins: atorvastatin, lovastatin, simvastatin | High vitamin D intake, especially from supplements, may reduce the effect of these statins; NIH notes a possible interaction. | Before starting or increasing a supplement dose, show its ingredients and vitamin D amount to a doctor or pharmacist and check compatibility with the specific statin. | [1] [4] |
More details
Combining supplements and medicines
Vitamin D helps calcium absorption, and calcium needs are assessed using the total diet. A requirement for everyone to combine vitamin D with magnesium or K2 has not been established. [1]
If you have high calcium, kidney disease or hyperparathyroidism, discuss vitamin D and all medicines with a doctor. Thiazide diuretics with vitamin D can raise blood calcium, particularly in older people and those with impaired kidney function or hyperparathyroidism. [1]
Orlistat with a reduced-fat diet may reduce vitamin D absorption. Corticosteroids can reduce calcium absorption and disrupt vitamin D metabolism, and high D doses may reduce the effect of some statins. [1]
The FDA label for Xenical says to take a multivitamin containing fat-soluble vitamins at least two hours before the medicine, two hours after it or at bedtime. Check your own medicine’s instructions. [1] [4] [5] [6]
Sources
- Vitamin D - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial. https://academic.oup.com/jcem/article/105/4/1261/5634116
- Corrigendum to: “Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial”. https://academic.oup.com/jcem/article/106/4/e1932/6095394
- Vitamin D - Consumer Fact Sheet. https://ods.od.nih.gov/factsheets/VITAMIND-Consumer/
- XENICAL (orlistat) capsules, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020766s039lbl.pdf
- Osteoporosis Inducida por Glucocorticoides. https://rheumatology.org/patients/osteoporosis-inducida-por-glucocorticoides
Methodology: Subpages evidence-led supplement pipeline v1